Основная статистика
| CIK | 1622996 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acro Biomedical Co., Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 (August 14, 2025) ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporati |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO. |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55643 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICA |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO. |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO |
|
| July 18, 2025 |
Description of the Company’s Common Stock EXHIBIT 4.1 Description of Capital Stock The authorized capital stock of Acro Biomedical Co., Ltd. (the “Company”) consists of 25,000,000 shares of preferred stock, par value $0.001 per share, and 100,000,000 shares of common stock, par value $0.001 per share. The following summary of the capital stock and the Company’s articles of incorporation and bylaws does not purport to be complete and is qu |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55643 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICA |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 (June 30, 2025) ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or |
|
| July 2, 2025 |
Letter to the Securities and Exchange Commission from Prager Metis CPAs, LLC dated July1, 2025 EXHIBIT 16.1 July 1, 2025 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read Item 4.01 of Form 8-K of Acro Biomedical Co., Ltd. dated July 1, 2025. We agree with the statements made concerning our firm contained therein. Yours very truly, /s/ Prager Metis CPAs, LLC Hackensack, New Jersey |
|
| November 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR For the Transition Period |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55643 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its |
|
| April 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICA |
|
| November 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 11-K ? Form 20-F ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR For the Transition Period |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55643 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its |
|
| April 1, 2022 |
NT 10-K 1 acront10k.htm FORM NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 10-Q ☐ Transition Report on |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICA |
|
| November 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR For the Transition Period |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55643 ACRO BIOMEDICAL CO. |
|
| August 17, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 11-K ? Form 20-F ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR For the Transition Period Ende |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| May 17, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 11-K ? Form 20-F T ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR For the Transition Period E |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55643 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its |
|
| April 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 11-K ☐ Form 20-F ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR For the Transition Period |
|
| February 26, 2021 |
SC 13D 1 acrosc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Acro Biomedical Co., Ltd. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 004892105 (CUSIP Number) Pao-Chi Chu 2F, No. 356, Dunhua S. Road, Da’an Dist Taipei City 106, Taiwan, Republic of China (86) 510-8339-7559 (Na |
|
| December 14, 2020 |
As filed with the Securities and Exchange Commission on December , 2020 Registration Statement No. |
|
| November 17, 2020 |
10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| November 17, 2020 |
NT 10-Q 1 acbmnt10q.htm NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 000-55643 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form |
|
| September 8, 2020 |
Description of the Company’s Common Stock(2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its charter) Nevada 47-1950356 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 12175 |
|
| August 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMEDICAL |
|
| August 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 11-K ☐ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR For the Transition Period End |
|
| August 13, 2020 |
ACRO BIOMEDICAL CO., LTD. 2020 EQUITY INCENTIVE PLAN EX-99.1 2 acbmex991.htm 2020 LONG-TERM INCENTIVE PLAN EXHIBIT 99.1 ACRO BIOMEDICAL CO., LTD. 2020 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Acro Biomedical Co., Ltd. 2020 Equity Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, managers, employees, consultants and adv |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Augusts 7, 2020 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or organization |
|
| May 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMEDICA |
|
| May 18, 2020 |
NT 10-Q 1 acbmnt10q.htm NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING ☐ Form 10-K ¨ Form 11-K ¨ Form 20-F ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N- |
|
| March 27, 2020 |
ACBM / Acro Biomedical Co., Ltd. 10-KT - - FORM 10-K 10-KT 1 acbm10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended or ☒ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from October 1, 2019 to December 31, 2019 Commission file num |
|
| January 17, 2020 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2020 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or organizatio |
|
| January 7, 2020 |
ACBM / Acro Biomedical Co., Ltd. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-207765 ACRO BIOMEDICAL CO., LTD. (Exa |
|
| December 31, 2019 |
ACBM / Acro Biomedical Co., Ltd. NT 10-K - - NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 11-K ¨ Form 20-F ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Perio |
|
| August 14, 2019 |
ACBM / Acro Biomedical Co., Ltd. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| May 15, 2019 |
ACBM / Acro Biomedical Co., Ltd. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMEDICA |
|
| February 14, 2019 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMED |
|
| December 28, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-207765 ACRO BIOMEDICAL CO., LTD. (Exa |
|
| October 22, 2018 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2018 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or organizatio |
|
| October 22, 2018 |
Letter to Securities and Exchange Commission from Paritz & Company, P.A., dated October 18, 2018 EX-16.1 2 acbmex161.htm EX-16.1 EXHIBIT 16.1 October 18, 2018 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read Item 4.01 of Form 8-K of Acro Biomedical Co., Ltd. dated October 18, 2018. We agree with the statements made concerning our firm contained therein. Yours very truly, /s/ Paritz & Company, P.A. Hackensack, New Jersey |
|
| August 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 1, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-Q (Quarterly Report) 10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| July 6, 2018 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2018 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or organization) ( |
|
| June 22, 2018 |
Letter to the Securities and Exchange Commission from MaloneBailey, LLP dated as of June 21, 2018 EXHIBIT 16.1 June 21, 2018 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of the Form 8-K for the event that occurred on June 19, 2018, of Acro Biomedical Co., Ltd. (formerly known as Killer Waves Hawaii, Inc.) and are in agreement with the statements contained therein as much as they relate to our firm. We have no basis to |
|
| June 22, 2018 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2018 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or organization) |
|
| May 16, 2018 |
ACBM / Acro Biomedical Co., Ltd. NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period En |
|
| March 16, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM S-1 AMENDMENT NO. 1 S-1/A 1 acbms1a1.htm FORM S-1 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 16, 2018 Registration No. 333-223046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in its charter) Nevada 2834 47-195 |
|
| February 15, 2018 |
As filed with the Securities and Exchange Commission on February ________, 2018 As filed with the Securities and Exchange Commission on February , 2018 Registration No. |
|
| February 14, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMED |
|
| January 16, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 33-18099-NY ACRO BIOM |
|
| January 16, 2018 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 33-18099-NY ACRO BIOMEDICAL CO., LTD. (Ex |
|
| January 16, 2018 |
EXHIBIT 10.1 Purchase Contract Party A: XIAMEN JINXIA YONGFENG COMMERCIAL CO.,LTD. Address: Rm. 908, Jutai Mansion, No. 1226, Xiahe Rd., Siming Dist., Xiamen City, Fujian Province, Chaina Party B: ACRO BIOMEDICAL CO., LTD. Address: 2175 Visionary Way, Suite 1160, Fishers, IN 46038, U.S.A. Party C: ACROLOGY INTERNATIONAL CO., LTD. Address: 14., Flat A, Lung Fung Court, No.363, Des Veoux Road West, |
|
| January 16, 2018 |
Purchase contract dated August 23, 2017, between the registrant and Aublog Inc. EXHIBIT 10.2 Purchase Contract Party A: ACRO BIOMEDICAL CO., LTD. Address: 2175 Visionary Way, Suite 1160, Fishers, IN 46038, U.S.A. Party B: Aublog Inc. Address: SF., No.2, Ln.7, Baogao Rd., Xindian Dist., New Taipei City, Taiwan, R.O.C. 1. Whereas Party A purchases Cordycepin (hereinafter referred to as the Product) from Party B, the specifications and price of the Product are specified in the A |
|
| January 16, 2018 |
EXHIBIT 10.1 Purchase Contract Party A: XIAMEN JINXIA YONGFENG COMMERCIAL CO.,LTD. Address: Rm. 908, Jutai Mansion, No. 1226, Xiahe Rd., Siming Dist., Xiamen City, Fujian Province, Chaina Party B: ACRO BIOMEDICAL CO., LTD. Address: 2175 Visionary Way, Suite 1160, Fishers, IN 46038, U.S.A. Party C: ACROLOGY INTERNATIONAL CO., LTD. Address: 14., Flat A, Lung Fung Court, No.363, Des Veoux Road West, |
|
| January 16, 2018 |
Purchase contract dated August 23, 2017, between the registrant and Aublog Inc. 2 EXHIBIT 10.2 Purchase Contract Party A: ACRO BIOMEDICAL CO., LTD. Address: 2175 Visionary Way, Suite 1160, Fishers, IN 46038, U.S.A. Party B: Aublog Inc. Address: SF., No.2, Ln.7, Baogao Rd., Xindian Dist., New Taipei City, Taiwan, R.O.C. 1. Whereas Party A purchases Cordycepin (hereinafter referred to as the Product) from Party B, the specifications and price of the Product are specified in the A |
|
| December 29, 2017 |
KWVH / Killer Waves Hawaii, Inc. FORM NT 10-K acbmnt10k.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING x Form 10-K ? Form 11-K ? Form 20-F ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR For the Tr |
|
| August 11, 2017 |
ACBM / Acro Biomedical Co., Ltd. FORM 10-Q (Quarterly Report) 10-Q 1 acbm10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| May 22, 2017 |
Killer Waves Hawaii FORM 10-Q (Quarterly Report) acbm10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 AC |
|
| May 16, 2017 |
kwhnt10q.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-207765 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 11-K ? Form 20-F x Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR For the Transit |
|
| May 12, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events 8-K 1 kwh8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2017 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorpo |
|
| May 12, 2017 |
EX-16.1 2 kwhex161.htm LETTER TO THE SECURITIES AND EXCHANGE EXHIBIT 16.1 May 10, 2017 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Acro Biomedical Co., Ltd. Ladies and Gentlemen: We have read the statements of Acro Biomedical Co., Ltd. (formerly Killer Waves Hawaii, Inc.) pertaining to our firm included under Item 4.01 of Form 8-K dated May 10, 2017 and agree wi |
|
| February 14, 2017 |
ACBM / Acro Biomedical Co., Ltd. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-207765 ACRO BIOMEDICA |
|
| February 1, 2017 |
Amended and Restated Articles of Incorporation of the Company.(1) acroex31.htm EXHIBIT 3.1 |
|
| February 1, 2017 |
Killer Waves Hawaii FORM 8-K (Current Report/Significant Event) acro8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2017 ACRO BIOMEDICAL CO., LTD. (Exact name of registrant as specified in Charter) Nevada 333-207765 47-1950356 (State or other jurisdiction of incorporation or |
|
| February 1, 2017 |
acroex32.htm EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF ACRO BIOMEDICAL CO., LTD (a Nevada Corporation) (adopted effective as of January 30, 2017) These Amended and Restated Bylaws of Acro Biomedical Co., Ltd., a Nevada corporation (the ?Corporation?) are adopted pursuant to Article X, Section .02 of the Corporation?s existing Bylaws, (the ?Original Bylaws?), and are intended to amend, restate and |
|
| January 26, 2017 |
CORRESP 1 filename1.htm KILLER WAVES HAWI’I, INC. PO Box 731 Lawai, HI 96765 VIA EDGAR January 26, 2017 Susan Block Attorney-Advisor US Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 RE: Killer Waves Hawaii, Inc. Post-Effective Amendment No. 1 to Registration Statement on Form S-1 File No. 333-207765 Dear Ms. Block: The undersigned registran |
|
| January 17, 2017 |
CORRESP 3 filename3.htm KILLER WAVES HAWI’I, INC. PO Box 731 Lawai, HI 96765 VIA EDGAR January 17, 2017 Susan Block Attorney-Advisor US Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Kill Waves Hawaii, Inc. Post-Effective Amendment to Form S-1 Filed December 21, 2016 File No. 333-207765 Dear Ms. Block: This letter is in response to your |
|
| January 14, 2017 |
Killer Waves Hawaii FORM S-1, POST EFFECTIVE AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1, POST-EFFECTIVE AMENDMENT NO. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KILLER WAVES HAWAII, INC (Exact name of registrant as specified in its charter) Nevada 7900 47-1950356 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. |
|
| December 21, 2016 |
Killer Waves Hawaii FORM S-1, POST EFFECTIVE AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1, POST -EFFECTIVE AMENDMENT NO. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KILLER WAVES HAWAII, INC (Exact name of registrant as specified in its charter) Nevada 7900 47-1950356 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. |
|
| December 16, 2016 |
Killer Waves Hawaii FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-155643 KILLER WAVES H |
|
| August 3, 2016 |
ACBM / Acro Biomedical Co., Ltd. 10-Q - Quarterly Report - FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarter Ended: June 30, 2016 Commission File Number: 333-207765 KILLER WAVES HAWAII, INC. (Exact name of small business issuer as specified in its charter) NEVADA 47-1950356 (State or other jurisdiction of incorporation or organization |
|
| May 13, 2016 |
ACBM / Acro Biomedical Co., Ltd. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 2016mar31-kwh10q.htm FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarter Ended: March 31, 2016 Commission File Number: 333-207765 KILLER WAVES HAWAII, INC. (Exact name of small business issuer as specified in its charter) NEVADA 47-1950356 (State or other jurisd |
|
| March 2, 2016 |
424B3 1 killerwavesprospectus.htm PROSPECTUS PROSPECTUS KILLER WAVES HAWAI’I, INC. 3,720,000 Shares of Common Stock $0.02 per share The date of this prospectus is February 29, 2016 This is our initial public offering of common stock of Killer Waves Hawai’i, Inc., a Nevada corporation (“we,” “us,” “our,” or the “Company”). We are registering a total of 3,720,000 shares of our common stock for sale |
|
| February 24, 2016 |
KILLER WAVES HAWI’I, INC. PO Box 731 Lawai, HI 96765 VIA EDGAR February 24, 2016 Justin Dobbie Legal Branch Chief US Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 RE: Killer Waves Hawaii, Inc. Registration Statement on Form S-1 File No. 333-207765 Dear Justin Dobbie: The undersigned registrant (the "Registrant") hereby requests that the Sec |
|
| February 18, 2016 |
KILLER WAVES HAWI?I, INC. PO Box 731 Lawai, HI 96765 VIA EDGAR February 17, 2016 Justin Dobbie Legal Branch Chief US Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Kill Waves Hawaii, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed December 31, 2015 File No. 333-207765 Dear Mr. Dobbie: This letter is in response to your c |
|
| February 18, 2016 |
Killer Waves Hawaii FORM S-1 AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1. PRE-EFFECTIVE AMENDMENT 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KILLER WAVES HAWAI?I, INC (Exact name of registrant as specified in its charter) Nevada 7900 47-1950356 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Empl |
|
| December 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1. PRE-EFFECTIVE AMENDMENT 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KILLER WAVES HAWAI?I, INC (Exact name of registrant as specified in its charter) Nevada 7900 47-1950356 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Empl |
|
| December 31, 2015 |
KILLER WAVES HAWI?I, INC. PO Box 731 Lawai, HI 96765 VIA EDGAR December 31, 2015 Justin Dobbie Legal Branch Chief US Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Kill Waves Hawaii, Inc. Registration Statement on Form S-1 Filed November 3, 2015 File No. 333-207765 Dear Mr. Dobbie: This letter is in response to your comment letter dated |
|
| November 3, 2015 |
Exhibit 3.1 |
|
| November 3, 2015 |
Letter from DKM Certified Public Accountants EX-16.1 5 ex-161.htm EX-16.1 Exhibit 16.1 2348 Sunset Point Rd. Suite B Clearwater, FL 33765 Telephone: 727.444.0931 855.334.0934 Toll free Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 November 2, 2015 We have read the statements included in the Form S-1 dated November 2, 2015, of Killer Waves Hawaii, Inc, to be filed with the Securities |
|
| November 3, 2015 |
BYLAWS KILLER WAVES HAWAII, INC a Nevada corporation ARTICLE I Exhibit 3.2 BYLAWS OF KILLER WAVES HAWAII, INC a Nevada corporation ARTICLE I Offices Section 1. Registered Office. The registered office of KILLER WAVES HAWAII, INC (the "Corporation") shall be maintained at such locations within the State of Nevada as the Board of Directors from time to time shall designate. The Corporation shall maintain in charge of such registered office an agent upon whom pr |
|
| November 3, 2015 |
S-1 1 killerwavess1.htm FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KILLER WAVES HAWAI’I, INC (Exact name of registrant as specified in its charter) Nevada 7900 47-1950356 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S |
